Codexis (CDXS) Tops Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Codexis Reports Financial Results for the Third Quarter of 2015
November 4, 2015 4:06 PM ESTRecords net income of $5.4 million on revenues of $17.4 million
Recognizes licensing agreement milestone payments totaling $11.5 million from GSK and Merck
Affirms 2015 revenue guidance and raises gross margin guidance
Conference call begins at 4:30 p.m. Eastern time today
REDWOOD CITY, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2015, and provides an update on the company's business progress.
"We are reporting strong financial and... More



